Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Upgraded by Oppenheimer

Oppenheimer upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a market perform rating to an outperform rating in a research report released on Monday morning, MarketBeat reports. Oppenheimer currently has $6.00 price target on the biopharmaceutical company’s stock.

A number of other research firms also recently weighed in on MRNS. StockNews.com raised Marinus Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, September 18th. LADENBURG THALM/SH SH lowered Marinus Pharmaceuticals from a buy rating to a neutral rating in a research note on Wednesday, August 14th. HC Wainwright restated a buy rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a research note on Wednesday, August 14th. Truist Financial reiterated a buy rating and set a $10.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. Finally, Cantor Fitzgerald restated an overweight rating and issued a $13.00 price target on shares of Marinus Pharmaceuticals in a research report on Monday, September 16th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of Hold and a consensus target price of $8.83.

Marinus Pharmaceuticals Stock Performance

Shares of NASDAQ MRNS opened at $1.73 on Monday. The firm has a market capitalization of $95.04 million, a price-to-earnings ratio of -0.66 and a beta of 1.13. Marinus Pharmaceuticals has a one year low of $1.05 and a one year high of $11.26. The business has a fifty day simple moving average of $1.40 and a 200 day simple moving average of $2.67. The company has a current ratio of 2.28, a quick ratio of 2.15 and a debt-to-equity ratio of 5.68.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The business had revenue of $8.06 million during the quarter, compared to analyst estimates of $9.05 million. During the same quarter in the prior year, the company posted ($0.61) EPS. Sell-side analysts expect that Marinus Pharmaceuticals will post -1.88 EPS for the current year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. Point72 DIFC Ltd acquired a new stake in shares of Marinus Pharmaceuticals in the second quarter valued at approximately $28,000. SG Americas Securities LLC acquired a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter valued at $34,000. AQR Capital Management LLC increased its stake in shares of Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 12,934 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Marinus Pharmaceuticals during the second quarter worth $64,000. Finally, Values First Advisors Inc. lifted its stake in shares of Marinus Pharmaceuticals by 501.8% during the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 52,257 shares during the period. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.